Main menu

Dr. Ali Behbahani is a Board Member at Tune Therapeutics, and a General Partner at New Enterprise Associates (NEA).

He specializes in investments in the biopharmaceutical and medical device sectors. Prior to NEA, he served as a business development consultant at The Medicines Company, as a Venture Associate with Morgan Stanley Venture Partners, and as a Healthcare Investment Banking Analyst with Lehman Brothers. He has been a Board Member at Nevro Corp., and a Member of the Board of Directors at Genocea Biosciences, Oyster Point Pharma, Adaptimmune, Black Diamond, and CRISPR Therapeutics.

Ali received his bachelor’s degrees in Biomedical Engineering, Electrical Engineering and Chemistry from Duke University; his M.B.A. from the Wharton School of the University of Pennsylvania; and his M.D. from the University of Pennsylvania School of Medicine.